Publication | Closed Access

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore

VaccinationVaccine SafetyCervical Cancer ScreeningCervical Cancer ManagementCost-effectiveness AnalysisCervical HealthHuman Papillomavirus VaccinesPreventive MedicineCervical CancerHealth EconomicsVaccine TrialVaccine EfficacyCost EffectivenessPublic HealthMedicineEpidemiologyCervical Cancer Prevention